Correlation of P16 (Ink4a) and CK17 to HPV (16E6+18E6 in Premalignant and Malignant Lesions of Uterine Cervix: A Clinicopathologic Study

Mohammed Kassim Chaloob¹, Alaa Ghani Hussein², Ban Jumaah Qasim²
1. Missan Health Directorate, Missan, Iraq
2. Dept. of Pathology and Forensic medicine, College of Medicine, Al-Nahrain University, Baghdad, Iraq

KEY WORDS
LSIL
HSIL
Cervical carcinoma
CK17
HPV(16E6+18E6)

ABSTRACT

Background: This research was accomplished to evaluate the IHC expression of p16 (ink4a) and CK17 in low grade cervical intraepithelial lesions (LSIL), high grade cervical intraepithelial lesions (HSIL) and invasive cervical carcinomas and to assess their correlation to HPV (16E6+18E6).

Methods: The study included (127) formalin-fixed paraffin-embedded cervical biopsies; of which 22 cases were chronic cervicitis, 24 cases were LSIL, 28 cases were HSIL and 53 cases were invasive cervical carcinomas. Sections were immunohistochemically stained for p16 (ink4a), CK17 and HPV (16E6+18E6).

Results: The study established a highly significant increase in IHC of expression of p16 (ink4a), CK17 and HPV (16E6+18E6) from LSIL through HSIL to invasive carcinomas (P-value˂0.001). There was non-significant association between IHC expression of all makers with age of patients; types, grade and stage of cervical carcinomas (P-value˃0.05). HPV (16E6+18E6) revealed a significantly positive correlation with p16 (ink4a) (P-value˂0.05) and a non- significant correlation with CK17 (P-value˃0.05); in LSIL, HSIL and invasive carcinoma cases.

Conclusion: p16 (ink4a) expression directly reflects infection with high risk HPV in cervical lesions and can add a significant diagnostic accuracy in the evaluation of CIN. CK 17 is a good marker of malignant transformation, with increasing in its expression according to the severity of cervical lesions; however, it is not related to HPV infection. Both markers are not related to prognostic variables of patients with cervical carcinoma.

Introduction

Cervical intraepithelial neoplasia (CIN) is a premalignant (dysplastic) lesion, which is marked with abnormal cell maturation and nuclear atypia (1). Majority of CIN lesions stay non-progressive, or are attacked by the host's defenses without therapy. Yet, a minority of lesions, without treatment, advance to invasive squamous cell carcinoma (SCC). The main etiological factor to CIN is chronic infection with high-risk human papilloma virus (HR-HPV) types 16 or 18 (2). Classification system has been lately customized to a simple two-tiered system, with low grade
squamous intraepithelial lesion (LSIL) and high grade squamous intraepithelial lesion (HSIL) (3).

HR-HPV genotypes are essential for cervical cancer progression and its late precursor lesion, CIN-III. HPV type 16 is the most carcinogenic genotype, detected in about 60% of cervical cancers, followed by HPV18 found in nearly 15% of cervical cancers (4, 5).

P16 (ink4a) is a cyclin dependent kinase inhibitor which coordinates transition from G1 to S phase of the cell cycle, acts as a tumor suppressor protein(6). P16 (ink4a) expression, which can be assessed immunohistochemically, is directly associated with HPV (7). Thus, this protein can help in the evaluation of CIN lesions (8). Cytokeratin 17 (CK17) is a type I (acidic) CK, its expression by mean of immunohistochemistry can assist in differentiating the grade of CIN lesions. In cervical carcinoma, CK 17 was always detected (9, 10).

The objective of this work was to study the expression of p16 (ink4a) and CK17 in LSIL, HSIL and invasive cervical carcinomas and to assess their correlation to HPV (16E6+18E6) expression in those lesions.

Materials and Methods

This study enrolled 127 formalin fixed paraffin embedded cervical biopsies; of which 22 cases were chronic cervicitis, 24 cases were LSIL (CIN-I), 28 cases were HSIL (CIN-II, 21 and CIN-III, 7) and 53 cases were invasive cervical carcinomas retrieved from the archival materials of two teaching hospitals for the period from January 2012 to October 2014.

This study was permitted by study Institutional Review Board of College of Medicine / Al-Nahrain University, which funded this study.

Twenty cases of LSIL were punch biopsies and 4 cases were cone biopsies. From cases of HSIL, 20 cases were punch biopsies, 6 cases were cone biopsies and 2 cases were total abdominal hysterectomy (TAH); for invasive cervical carcinomas 45 cases were TAH, 6 cases were punch biopsies and 2 cases were cone biopsy.

Clinicopathological data (age; grade of cervical neoplasia; histopathological type, grade and FIGO (International Federation of Gynecology and Obstetrics) pathological stage of cervical carcinomas) were collected from patients’ reports.

From each paraffin block, 4 representative (4 micrometer) sections were obtained, one section was stained with Hematoxylin and Eosin (H&E) and revised by a pathologist and the remaining three were subjected to immunohistochemical testing for : anti-HPV (16 E6+18 E6) antibody, clone (C1P5), anti-P16 (ink4a) antibody, clone (2D9A12) and anti-CK 17 antibody, clone (E3); all manufactured by Abcam.

Interpretation of the results of immunohistochemical staining

HPV (16E6+18E6)

Brown nuclear staining or combined nuclear and cytoplasmic staining is considered positive reaction. Cytoplasmic staining only was considered as negative (11, 12). Positive control is cervical carcinoma known to be positive for HPV (16 and/or 18). Scoring of IHC expression of HPV (16E6+18E6) was performed using an arbitrary semi-quantitative scale: (−), no staining observed representing negative staining; <25% representing mild positive staining (+); 25%–50% representing moderate positive staining (++); >50% representing extensive (+++) immunostaining(13).

P16 (ink4a)

Brown nuclear and cytoplasmic staining is considered positive. Positive control is astrocytoma. Scoring was semi-quantitative based on
the following:

The intensity scales: 0=no staining; 1=weak focally positive; 2=strong, focally positive or weak, diffusely positive and 3= strong, diffusely positive. Percentage of positive nuclear staining scales: 1=1-25%, 2=26-50%, 3=51-75%, and 4=76-100%. Final score ranges from 0, 2-7 (14).

CK17

Brown cytoplasmic staining is considered positive. Positive control is squamous cell carcinoma. Technical negative control was obtained by omission of primary antibody. The IHC expression of CK 17 was assessed semi-quantitatively by taking the percentage of stained cells. Cases showing <5% positive cells were regarded as negative, and those having > 5% positive cells were considered positive. Scores were counted as the following: mild (+) when 5–30 % positive cells, moderate (++) when 31–60 % positive cells and strong (+++) when more than 60 % positive cells (15).

Technical negative controls for all markers were prepared by exclusion of primary antibody.

Statistical Analysis

Statistics was accomplished with SPSS V. 17 (Chicago, IL, USA) and Excel 2007 programs. Continuous variables were calculated as mean ± SEM (standard error of the mean), while categorical variables were expressed as numbers and percentages. Statistical relations between two categorical variables were tested using Chi-square or Fisher exact tests. Relations between categorical and continuous variables were tested using unpaired t-test and ANOVA. The correlations between various markers were tested using Spearman rank correlation.

Results

The clinicopathological data of LSIL, HSIL and carcinoma cases are summarized in Table 1.

HPV (16E6+18E6) immunohistochemical expression

HPV (16E6+18E6) IHC was negative in all of the cases.

Table 1

Clinicopathological data of LSIL, HSIL and invasive cervical carcinoma cases

| Clinicopathological data                                      | Values          |
|--------------------------------------------------------------|-----------------|
| Age :Mean (range ± SEM) years                                |                 |
| LSIL                                                         | 38.46±2.3       |
| (22-62)                                                       |                 |
| HSIL                                                         | 43.32±1.92      |
| (27-63)                                                       |                 |
| Invasive cervical carcinoma                                  | 44.13±1.4       |
| (29-70)                                                       |                 |
| Histopathological types of invasive cervical carcinoma        |                 |
| Adenocarcinomas                                              | 12 (22.64%)     |
| Adenosquamous carcinomas                                     | 3 (5.66%)       |
| Squamous cell carcinomas                                     | 38 (71.7%)      |
| Grade of invasive cervical carcinoma                         |                 |
| Well-differentiated                                           | 9 (16.98%)      |
| Moderately-differentiated                                    | 28 (52.83%)     |
| Poorly-differentiated                                        | 16 (30.19%)     |
| Stage of invasive cervical carcinoma (pathological FIGO staging system)* |                   |
| I                                                            | 13 (29%)        |
| II                                                           | 24 (53%)        |
| III                                                          | 8 (18%)         |

SEM: standard error of the mean, LSIL: low grade squamous intraepithelial lesion, HSIL: high grade squamous intraepithelial lesion, *8 out of 53 carcinoma patients were lacking information about the stage (6 cases were punch biopsies and 2 cases were cone biopsies).
the cases of chronic cervicitis, however, it was significantly increased in expression with rising severity of the lesions from LSIL to HSIL; and the highest expression was noted in carcinomas ($P<0.001$). HPV (16E6+18E6) was expressed in 7 out of 24 LSIL cases (29.2%) while in HSIL, 13 cases out of 28 (46.4%) were positive for HPV (16E6+18E6) immunostaining (Figure 1). Positive HPV (16E6+18E6) expression was seen in 36 out of 53 carcinoma cases (67.9%) (Figure 2). The difference in the distribution of cases according to scores of IHC expression of HPV (16E6+18E6) was highly statistically significant ($P<0.001$) (Table 2).

Statistical analysis recorded non-significant association between age and IHC expression of HPV (16E6+18E6) in studied squamous intraepithelial lesion (SIL) and carcinoma cases, ($P=0.558$) and ($P=0.518$), respectively. There was also non-significant association of HPV (16E6+18E6) expression with histopathological types ($P=1$), grade ($P=1$) and FIGO pathological stage of invasive cervical carcinomas ($P=0.442$) (Table 3).

Table 2
Frequency distribution of LSIL, HSIL and invasive cervical carcinoma cases according to immunohistochemical expression and scoring of immunostaining of HPV (16E6+18E6)

| Frequency of HPV (16E6+18E6) expression and scores | LSIL No. (%) | HSIL No. (%) | Carcinoma No. (%) |
|---------------------------------|--------------|--------------|------------------|
| Positive                        | 7 (29.2)     | 13 (46.4)    | 36 (67.9)        |
| Negative                        | 17 (70.8)    | 15 (53.6)    | 17 (32.1)        |
| Mild (+)                        | 4 (16.7)     | 3 (10.7)     | 4 (7.5)          |
| Moderate (++)                   | 1 (4.2)      | 4 (14.3)     | 9 (17)           |
| Extensive (+++)                 | 2 (8.3)      | 6 (21.4)     | 23 (43.4)        |
| Total                           | 24           | 28           | 53               |
| $P$-value                       | <0.001       |              |                  |

Table 3
Frequency distribution of LSIL, HSIL and invasive cervical carcinoma cases according to immunohistochemical expression and scoring of immunostaining of p16 (ink4a)

| Frequency of p16 (ink4a) expression and scores | LSIL No. (%) | HSIL No. (%) | Carcinoma No. (%) |
|-----------------------------------------------|--------------|--------------|------------------|
| Positive                                      | 7 (29.2)     | 13 (46.4)    | 36 (67.9)        |
| Negative                                      | 17 (70.8)    | 15 (53.6)    | 17 (32.1)        |
| Mild (+)                                      | 4 (16.7)     | 3 (10.7)     | 4 (7.5)          |
| Moderate (++)                                 | 1 (4.2)      | 4 (14.3)     | 9 (17)           |
| Extensive (+++)                               | 2 (8.3)      | 6 (21.4)     | 23 (43.4)        |
| Total                                         | 24           | 28           | 53               |
| $P$-value                                     | <0.001       |              |                  |

p16 (ink4a)immunohistochemical expression

Descriptive analysis discovered a highly significant increase in the IHC expression of p16 (ink4a) from LSIL (37.5%) through HSIL (67.9%) to carcinomas (94.3%), ($P<0.001$),
With reference to the score of p16 (ink4a) IHC expression; high scores (6-7) were noticed in 2 out of 24 LSIL cases (8.3%), 7 out of 28 HSIL cases (25%) (Figure 3) and 25 out of 53 cases of cervical carcinoma (47.2%) (Figures 4, 5). The difference in the frequency distribution of the cases is highly significant ($P<0.001$) (Table 4).

Results exposed non-significant association of p16 (ink4a) expression with age of patients in both SILs and invasive carcinomas, ($P=0.378$) and ($P=0.247$), respectively. p16 (ink4a) expressions were not statistically different according to histopathological types, grade and FIGO pathological stage of invasive cervical carcinomas, ($P=1$), ($P=0.570$), ($P=0.107$), respectively (Table 5).

**Table 3**
Association of HPV (16E6+18E6) immunohistochemical expression with clinicopathological parameters of SILs, and invasive cervical carcinomas

| Clinicopathological parameter | Positive HPV (16E6+18E6) | Negative HPV (16E6+18E6) | $P$-value |
|------------------------------|---------------------------|---------------------------|-----------|
| Age (yr) (mean±SEM)          |                           |                           |           |
| SIL                          | 39.85±2.55                | 38±1.9                    | 0.558     |
| Invasive carcinoma           | 37.83±1.97                | 39.94±2.17                | 0.518     |

| Histopathological type of invasive carcinomas | Adenocarcinoma | Adenosquamous | Squamous |
|-----------------------------------------------|----------------|---------------|---------|
| No. (%)                                       | 8 (66.7%)      | 2 (66.7%)     | 26 (68.4%) |
|                                                | 4 (33.3%)      | 1 (33.3%)     | 12 (31.6%) |

| Grade of invasive carcinoma | Well-differentiated | Moderately-differentiated | Poorly-differentiated |
|-----------------------------|---------------------|----------------------------|----------------------|
| No. (%)                     | 6 (66.7%)           | 19 (67.9%)                 | 11 (68.8%)           |
|                             | 3 (33.3%)           | 9 (32.1%)                  | 5 (31.2%)            |

| Pathological stage of invasive carcinoma | I | II | III |
|-----------------------------------------|---|----|-----|
| No. (%)                                 | 8 (61.5%) | 15 (62.5%) | 7 (87.5%) |
|                                         | 5 (38.5%) | 9 (37.5%) | 1 (12.5%) |

SILs: squamous intraepithelial lesion, SEM: standard error of the mean, No.: number

Fig. 3
HSIL of the uterine cervix stained immunohistochemically with anti-p16 (ink4a) monoclonal antibody showing positive brown nuclear (red arrow) and cytoplasmic (blue arrow) staining with moderate intensity (2), high percentage (4) and score (6), (40X).

(***Table 4***). None of the cases of chronic cervicitis showed positive immunoreactivity to p16 (ink4a).

**CK17 immunohistochemical expression**

CK17 showed a negative expression in all
cases of chronic cervicitis with significant increment in its expression with rising severity of the lesions from LSIL (10 cases out of 24 (41.7%)) (Figure 6) through HSIL (20 cases out of 28 (71.4%)) (Figure 7) to carcinomas (48 cases out of 53 (90.6%)) (Figure 8) had been recognized; ($P<0.001$), (Table 6).

Concerning score of CK17 IHC staining, none of the cases of LSIL showed strong (++++) expression. In HSIL cases, CK17 reported strong expression in 7 cases (25%) (Figure 7) while CK17 was expressed strongly in 26 carcinoma cases (49.1%) (Figure 8). The difference is this distribution was highly statistically significant ($P<0.001$) (Table 6).

Current research established a non- significant association between age and IHC expression of CK17 in studied SILs and carcinomas, ($P=0.913$) and ($P=0.948$), respectively. There was also non- significant difference in CK17 IHC expression among different histopathological types ($P=0.691$), different grades ($P=0.442$) and pathological FIGO stage ($P=0.631$) of cervical carcinoma (Table 7).

### Table 4

| Expression of p16(ink4a) and Scores | LSIL No. (%) | HSIL No. (%) | Carcinomas No. (%) |
|------------------------------------|-------------|-------------|-------------------|
| Positive                           | 9 (37.5)    | 19 (67.9)   | 50 (94.3)         |
| Negative                           | 15 (62.5)   | 9 (32.1)    | 3 (5.7)           |
| 2                                  | 2 (8.3)     | 3 (10.7)    | 9 (17)            |
| 3                                  | 3 (12.5)    | 2 (7.1)     | 7 (13.2)          |
| 4                                  | 1 (4.2)     | 4 (14.3)    | 4 (7.5)           |
| 5                                  | 1 (4.2)     | 3 (10.7)    | 5 (9.4)           |
| 6                                  | 2 (8.3)     | 4 (14.3)    | 10 (18.9)         |
| 7                                  | 0 (0)       | 3 (10.7)    | 15 (28.3)         |
| Total                              | 24          | 28          | 53                |

*P*-value: $<0.001$

LSIL: low grade squamous intraepithelial lesion, HSIL: high grade squamous intraepithelial lesion, No.: number

---

**Fig. 4**

Moderately differentiated adenocarcinoma of the uterine cervix stained immunohistochemically with anti-p16 (ink4a) monoclonal antibody showing positive brown nuclear (red arrow) and cytoplasmic (blue arrow) staining with strong intensity (3), high percentage (4) and score (7), (40X).

**Fig. 5**

Poorly differentiated cell squamous carcinoma of the uterine cervix stained immunohistochemically with anti-p16 (ink4a) monoclonal antibody showing positive brown nuclear (red arrow) and cytoplasmic (blue arrow) staining with strong intensity (3), high percentage (4) and score (7), (40X).
Table 5
Association of p16 (ink4a) immunohistochemical expression with clinicopathological parameters of SILs, and invasive cervical carcinomas

| Clinicopathological parameter | Positive p16 (ink4a) | Negative p16 (ink4a) | P-value |
|------------------------------|----------------------|----------------------|---------|
| **Age (years) (mean±SEM)**   |                      |                      |         |
| SIL                          | 39.96±2.15           | 37.25±2.14           | 0.378   |
| Invasive carcinoma           | 38.08±1.56           | 45.67±4.06           | 0.247   |
| **Histopathological type of invasive carcinomas** | | | |
| Adenocarcinoma               | 11 (91.7%)           | 1 (8.3%)             |         |
| Adenosquamous                | 3 (100%)             | 0 (0%)               | 1.000   |
| Squamous                     | 36 (94.7%)           | 2 (5.3%)             |         |
| **Grade of invasive carcinoma** | | | |
| Well-differentiated          | 8 (88.9%)            | 1 (11.1%)            |         |
| Moderately-differentiated    | 26 (92.9%)           | 2 (7.1%)             | 0.570   |
| Poorly-differentiated        | 16 (100%)            | 0 (0%)               |         |
| **Pathological stage of invasive carcinoma** | | | |
| I                            | 11 (84.6%)           | 2 (15.4%)            |         |
| II                           | 24 (100%)            | 0 (0%)               | 0.107   |
| III                          | 8 (100%)             | 0 (0%)               |         |

SILs: squamous intraepithelial lesion, SEM: standard error of the mean, No.: number

Table 6
Frequency distribution of LSIL, HSIL and invasive cervical carcinoma cases according to immunohistochemical expression and scoring of immunostaining of CK17

| Expression of CK17 and scores | LSIL No. (%) | HSIL No. (%) | Carcinoma No. (%) |
|-------------------------------|--------------|--------------|-------------------|
| Positive                      | 10 (41.7)    | 20 (71.4)    | 48 (90.6)         |
| Negative (0)                  | 14 (58.3)    | 2 (7.1)      | 5 (9.4)           |
| Mild (+)                      | 8 (33.3)     | 2 (7.1)      | 7 (13.2)          |
| Moderate(++)                  | 2 (8.3)      | 11 (39.3)    | 15 (28.3)         |
| Strong (+++)                  | 0 (0)        | 7 (25)       | 26 (49.1)         |
| **Total**                     | 24           | 28           | 53                |

P-value: <0.001

LSIL: low grade squamous intraepithelial lesion, HSIL: high grade squamous intraepithelial lesion, No.: number

Fig. 6
LSIL of the uterine cervix showing brown staining of cytoplasm with anti-Ck17 monoclonal antibody (arrows) with moderate intensity(++) into the lower third of the squamous epithelium, (10X).

Fig. 7
HSIL of the uterine cervix showing brown staining of cytoplasm with anti-Ck17 monoclonal antibody (arrows) with strong intensity (+++) of the whole thickness of the squamous epithelium, (40X).
Table 7
Frequency distribution of LSIL, HSIL and invasive cervical carcinoma cases according to immunohistochemical expression and scoring of immunostaining of p16 (ink4a)

| Clinicopathological parameter | Positive CK17 | Negative CK17 | P-value |
|-------------------------------|---------------|---------------|---------|
| Age (years) (mean±SEM)        |               |               |         |
| SIL                           | 38.57±1.8     | 38.91±2.68    | 0.913   |
| Invasive carcinoma            | 38.54±1.54    | 38.2±6.62     | 0.948   |
| Histopathological type of invasive carcinomas | | | |
| Adenocarcinoma No. (%)        | 10 (83.3%)    | 2 (16.7%)     | 0.691   |
| Adenosquamous No. (%)         | 3 (100%)      | 0 (0%)        |         |
| Squamous No. (%)              | 35 (92.1%)    | 3 (7.9%)      |         |
| Grade of invasive carcinoma   |               |               |         |
| Well-differentiated No. (%)   | 7 (77.8%)     | 2 (22.2%)     |         |
| Moderately-differentiated No. (%) | 26 (92.9%) | 2 (7.1%) | 0.442   |
| Poorly-differentiated No. (%) | 15 (93.8%)    | 1 (6.2%)      |         |
| Pathological stage of invasive carcinoma | | | |
| I No. (%)                     | 11 (84.6%)    | 2 (15.4%)     |         |
| II No. (%)                    | 22 (91.7%)    | 2 (8.3%)      | 0.107   |
| III No. (%)                   | 8 (100%)      | 0 (0%)        |         |

Table 8
Correlation between HPV (16E6+16E8) and p16 (ink4a), CK17 IHC expressions in SIL and cervical carcinoma

| Other markers | HPV (16E6+16E8) in SIL | HPV (16E6+16E8) in cervical carcinoma |
|---------------|-------------------------|---------------------------------------|
|               | r | P  | r  | P   |
| p16(ink4a)    | 0.869 | <0.001 | 0.939 | <0.001 |
| CK17          | -0.256 | 0.067 | 0.040 | 0.775 |

SILs: squamous intraepithelial lesion, SEM: standard error of the mean, No.: number

Correlation between of HPV (16E6+18E6) and p16 (ink4a), CK17 IHC expressions in SIL and carcinoma cases

In SIL cases, HPV (16E6+18E6) expression significantly correlated with the expression of p16 (ink4a), (P<0.001). Nevertheless, CK17 showed non-significant with of HPV (16E6+18E6), (P=0.067) (table 8).

Pertaining to cervical carcinoma cases, results distinguished a significant correlation between IHC expression of HPV (16E6+18E6) and IHC expression of p16 (ink4a) (P<0.001). The correlation between HPV (16E6+18E6) and CK17 IHC expression was non-significant (P=0.775)
Discussion

In Iraq, during the period 1976-1985, the cervical cancer ranked the sixth among the commonest 10 cancers in females (16), whereas throughout the period 1995-1997, it ranked the tenth within the leading cancer in females. Cervical cancer constitutes 1.4% of the total number of cancers with annual number of 113 new cases reported in 1995, 1996, and 1997, respectively (17). Nowadays and according to the latest Iraqi cancer registry, 2011, cervical cancer is out of the commonest ten cancers in Iraqi females (18).

Although this study is not a large epidemiological one that expresses the prevalence and incidence of HPV (16+18) according to different clinicopathological parameters of cervical lesions; but in general HPV (16E6+18E6) was significantly increased in its expression with mounting severity of the lesions from LSIL (29.2%) through HSIL (46.4%) to carcinomas (67.9%).

Activity of HPV infection is determined through early gene products’ expression to be active or latent or leads to malignant transformation (19). The E6 protein targets the degradation of p53 and thereby conquering the cellular arrest and p53 proapoptotic activities (20). One of the mechanisms of p53 inactivation is through the inhibition of binding of p53 to its target gene sequence (21).

In an Iraqi study completed in Baghdad using ISH technique (22), HPV (16) was recovered in 40% of SIL cases without detection of HPV (18) and in 75% of carcinoma cases. In another Iraqi study using PCR technique (23), HPV (16+18) was detected in SILs and squamous cell carcinomas in 50% and 60%, respectively.

In an Iranian meta-analysis study (including 20 studies) (24), the prevalence of HPV (16+18) in Iranian female patients with normal cervix, LSIL, HSIL and invasive carcinomas were (4.9%), (53.4%), (64.5%) and (64.5%), respectively. In Saudi Arabia using PCR technique, the prevalence of HPV (16+18) in invasive cervical cancer was (78.7%) and (74.5%), respectively (25, 26). In a Turkish research, HPV-16 and HPV-18 were detected in 41.4% and 10.5% of LSIL, respectively; and in 68.8% and 4.2% of HSIL, correspondingly (27).

In an Indian works (28), and Sowjanya et al. (29), using PCR technique, the HPV (16+18) were detected in 79.3% and 86.1% of cervical carcinomas, respectively. In a Brazilian research using PCR technique, HPV-16 and HPV-18 were detected in 77.6% and 12.3% of cervical carcinomas, respectively (30).

In a retrospective international survey including 38 countries during the period 1949-2009, the prevalence of HPV (16+18) in invasive cervical cancer detected by PCR technique in Europe, North America (USA), central South America, Africa, Asia and Australia were 73%, 79%, 68%, 71%, 7% and 79%, in that order (7).

The result of the current article is almost parallel to other Iraqi studies and studies done in neighboring Islamic countries. The frequency of HPV (16+18) in the current study is lower than other countries like Brazil, India, Turkey, Europe, USA and Australia and this is possibly due to difference in sample size, use of more sensitive methods for detecting HPV (16+18) like ISH and PCR compared to IHC method which was used in this study and may be attributable to the unique religious and cultural restrictions preventing women to have multiple sexual partners in Iraq, thus reducing unsafe sexual relationships therefore lowering the threat of HPV infection.

This study reported non-significant connection of age and HPV (16E6+18E6) expression in studied SIL and carcinoma cases. This outcome is regular with other authors (29, 31). The prevalence of HR-HPV was more common in younger age women, this difference could be attributed
to environmental, racial and different age at first intercourse (30).

The early age of the first sexual practice is unquestionably related to HPV infections (32). The immature transitional zone of the developing cervix (perimenarche) or cervix healing from delivery, trauma or infections, are at high risk for an HPV infection (33).

The current research showed IHC expression of HPV (16E6+18E6) in 66.7% of adenocarcinomas, 66.7% of adenosquamous carcinomas and in 68.4% of squamous carcinomas with no significant difference ($P=1$). Those findings are in accordance to another Iraqi article (26, 30).

There was non-significant difference in IHC expression of HPV (16E6+18E6) between the grade and pathological stage of studied cervical carcinoma cases in the present study. This result is accordance with the results obtained from other studies (34-36).

P16 (ink4a) was also significantly increased in its expression from LSIL (37.5%) through HSIL (67.9%) to carcinomas (94.3%). This result is in agreement with several other studies (37-42). In a study done on 59 cases of different cervical lesions (14), no significant difference in IHC expression of p16 (ink4a) between CIN lesions and cervical carcinomas had been observed, this discrepancy is probably due to ecological, cultural and geological variations, as well as sample size.

p16 overexpression could reveal the potential for cervical malignant transformation as it is augmented with higher CIN grade (38). In cervical lesions induced by HPV, viral oncoprotein E7 interacts and inactivates pRb. Consequently, inactivated pRb passes the cell cycle checkpoint G1/S with no difficulty. Functionally active gene Rb is found to be a factor in the negative regulation of the expression of INK4a on a transcriptional level (43, 44). Also rising p16 expression may well reflect additional strong inactivation of pRb by HR-HPV that commonly result in progression of CIN (45).

Concerning the age, the current work revealed no significant association between age and IHC expression of p16 (ink4a) in both studied SILs and carcinoma cases. This data is in harmony with other authors (14).

On the subject of cervical carcinoma cases, the present study recorded non-significant difference in IHC expression of p16 (ink4a) among different histopathological types, grade and pathological stage of studied cervical carcinoma cases. These results were also observed by other researches (14, 40).

The current work established that p16 (ink4a) is highly correlated with HPV (16E6+18E6) in SILs and cervical carcinoma cases, respectively. This result is akin to that obtained by other studies (46-49).

P16 (ink4a) is a cell cycle inhibitor that binds to cdk4 and cdk6 that inhibits pRb phosphorylation and inactivation (50). The down regulation of p16 (ink4a) is linked to the pathogenesis of cancers in various organs (51, 52). Yet, overexpression of p16 (ink4a) is usually found in pre-malignant cervical lesions and cancers (53).

Through a negative feedback mechanism, E6 and E7 proteins can cause induce production of p16 (ink4a), as they bind to pRb and inactivate it (53). HPV-E7 proteins leads to functional inactivation of pRb and thereby causing p16 (ink4a) expression in cervical lesions (50). Using a panel of p16 (ink4a)- specific monoclonal antibodies, p16 (ink4a) is specifically overexpressed in CIN lesions infected with HR-HPV and in carcinomas, but not in normal cervix or inflammatory lesions (54).

CK 17 is present in cervical reserve cells (from which CIN is originated). Its expression in term of percentage and intensity is increase with increasing severity of CIN. In cervical carcinoma, keratin 17 was always detected, so the development of carcinoma from CIN-III is restricted to CK17 positive CIN-III (9, 10).

This work set up positive expression of CK 17
in all cases of SIL and carcinomas, with significant augment in its expression with increasing severity of the lesions from LSIL (41.7%) through HSIL (71.4%) to cervical carcinomas (90.6%). This result is nearly analogous to that obtained earlier (55), who found IHC expression of CK17 in 33.3% of CIN-I, 58.1% of CIN-II, 81.4% of CIN-III and in 95.2% of squamous cell carcinoma. In a research (56), CK17 was not found in non-neoplastic cervix and its expression was increased significantly from CIN-III to invasive carcinoma. CK 17 was detected in the lowermost parts of CIN lesions with different grades in up to half of cases with its higher expressions in reserve cells and reserve cell hyperplasia where cervical epithelial stem cells reside assessing the importance of CK 17 as stem cell marker (57).

Taking age into consideration, this study reported non-significant association between age and IHC expression of CK17 in SILs and carcinomas, that is in tune with Ikeda et al., 2008 (55).

The current paper showed non-significant difference in IHC expression of CK17 among different histopathological types, grade and pathological stage of cervical carcinoma that is in unity with other authors; (Carrilho et al., 2004) (56), and (Maddox et al., 1999) (58).

CK 17 was not correlated to IHC expression of HPV (16E6+18E6) in the studied SILs and carcinoma cases, that is in concord with other studies (46, 59). Missing the correlation of CK 17 with HPV (16+18) indicates that this marker is of cervical dysplastic tissues and not of cervical infection by HPV (59).

**Conclusion**

p16 (ink4a) expression directly reflects infection with high risk HPV in cervical lesions and can add a significant diagnostic accuracy in the evaluation of CIN. CK 17 is a good marker of malignant transformation, with increasing in its expression according to the severity of cervical lesions; however, it is not related to HPV infection. Both markers are not related to prognostic variables of patients with cervical carcinoma.

**Acknowledgment**

To the College of Medicine /Al-Nahrain University including its deanery for the financial support to this study and the staff of the teaching laboratories of Department of Pathology and Forensic Medicine for their help in providing materials for this research and for the technical aid.

**Author contributions**

All authors contributed to this manuscript. They shared the concept of the research protocol, accomplishment and steps forward of this study, and cooperated in analysis of results and writing the article for future publishing.

**Conflict of Interest**

The authors declare that there is no conflict of interests.

**References**

1. Madhumati G, Kavita S, Anju M, Uma S, Raj M. Immunohistochemical Expression of Cell Proliferating Nuclear Antigen (PCNA) and p53 Protein in Cervical Cancer. J Obstet Gynaecol India 2012; 62:557-61.
2. Agorastos T, Miliaras D, Lambropoulos AF, Chrisafi S, Kotsis A, Manthos A, et al. Detection and typing of human papilloma virus DNA in uterine cervices with coexistent grade I and grade III intraepithelial neoplasia: biologic progression or independent lesions? Eur J Obstet Gynecol Reprod Biol 2005; 121:99-103.
3. Ellenson LH, Pirog EC. The Female Genital Tract. In: Kumar V, Abbas KA, Fausto N, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 8th ed. Philadelphia, PA: Elsevier Saunders, 2010;pp1018-24.
4. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048-56.

5. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27.

6. Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, et al. p16 (INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009; 35:210-20.

7. Rabban JT, Soslow RA, Zaloudek CZ. Diagnostic immunohistochemistry of the female genital tract. In: Dabbs DJ, Ed. Diagnostic Immunohistochemistry. 3rd ed. Churchill Livingstone: Philadelphia 2010: pp690-9.

8. Benevolo M, Mottolese M, Marandino F, Vocature G, Sindico R, Piperno G, et al. Immunohistochemical expression of p16 (INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol 2006;19:384-91

9. Smedts F, Ramaekers F, Link M, Laueroa L, Trojanovsky S, Schijf C, et al. Detection of keratin subtypes in routinely processed cervical tissue: implications for tumor classification and the study of cervix cancer etiology. Virchows Arch 1994; 425:145-55.

10. Smedts F, Ramaekers F, Trojanovsky S, Pruszczynski M, Robben H, Lane B, et al. Basal-cell keratins in cervical reserve cells and a comparison to their expression in cervical intraepithelial neoplasia. Am J Pathol 1992; 140:601-12.

11. Yang Y, Sabata B, Monroe R, Chang T, Hsiao L, Jung S, et al. Digital analysis of IHC images for detecting HPV E6/E7 oncoproteins in CIN2/3 and cervical cancer tissues. The 26th Internation Papillomavirus Conference, Canada, Onco Health 2010: 461.

12. Agrawal GP, Joshi PS, Agrawal A. Role of HPV-16 in pathogenesis of oral epithelial dysplasia and oral squamous cell carcinoma and correlation of p16INK4A expression in HPV-16 positive cases: an immunohistochemical study. ISRN Pathology. 2013; Article ID 807095, 7 pages. http://dx.doi.org/10.1155/2013/807095

13. Chaudhary AK, Pandya S, Singh M, Singh M, Mehrutra R. Identification of high-risk human papillomavirus (HPV-16 & 18) infection by multiplex PCR (MPX-PCR) and its expression in oral sub mucous fibrosis and oral squamous cell carcinoma. Head Neck Oncol 2013; 5:4.

14. Shin EA, Lee SR, Lee SY, Kim NH, Ju W, Kim SC. p16INK4a methylation and the correlation to immunohistochemical expression in cervical neoplasia. J Womens Med 2009; 2: 16-22.

15. Kitamura R, Toyoshima T, Tanaka H, Kawano S, Kiyosue T, Matsubara R, et al. Association of cytokertatin 17 expression with well differentiation in oral squamous cell carcinoma. J Cancer Res Clin Oncol 2012; 138:1299-310.

16. Iraqi Cancer Board. Results of Iraqi Cancer Registry, 1976-1985. Ministry of Health (editor), Baghdad, Iraq 1987:18, 35, 59.

17. Iraqi Cancer Board. Results of Iraqi Cancer Registry, 1995-1997. Ministry of Health (editor), Baghdad, Iraq 1999:11-13, 34, 32-39.

18. Iraqi Cancer Board. Results of Iraqi cancer registry center, 2011. Ministry of Health (editor), Baghdad, Iraq 2014.

19. Anderson SM. Human papillomavirus and cervical cancer. Clinical Microbiology Newsletter.2002; 24: 113-8.

20. Thomas MC, Chiang CM. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 2005; 17:251-64.

21. Kumar A, Zhao Y, Meng G, Zeng M, Srinivasan S, Delmolino LM, et al. Human papillomavirus oncoprotein E6 inactivates the transcriptional co-activator human ADA3. Mol Cell Biol 2002; 22:5801-12.

22. Al-jewari MMM, Ali SHM, Al-azzawi MKK. Genotyping of human papilloma virus infections and phenotyping of tumor infiltrating lymphocytes in Iraqi patients with uterine cervical neoplasia. Iraqi Postgraduate Medical Journal 2007; 6: 362-73.

23. Fahad RO, Abdulbaqi S, Hasony HJ. The association of human papillomavirus with cervical neoplasm in Basrah. Basrah Journal of Surgery,2011; 17: 14-21.
24. Jalilvand S, Shoja Z, Nourijelyani K, Tohidi HR, Hamkar R. Meta-analysis of type-specific human papillomavirus prevalence in Iranian women with normal cytology, precancerous cervical lesions and invasive cervical cancer: Implications for screening and vaccination. J Med Virol 2015; 87:287-95.

25. Alsbeih G, Ahmed R, Al-Harbi N, Venturina LA, Tulbah A, Balaraj K. Prevalence and genotypes distribution of human papillomavirus in invasive cervical cancer in Saudi Arabia. Gynecol Oncol 2011; 121:522-6.

26. Al-Badawi IA, Al-Suwaine A, Al-Aker M, Asaad L, Alaidan A, Tulbah A, et al. Detection and genotyping of human papilloma virus in cervical cancer specimens from Saudi patients. Int J Gynecol Cancer 2011; 21:907-10.

27. Dursun P, Ayhan A, Mutlu L, Çağlar M, Haberal A, Güngör T, et al. HPV types in Turkey: multicenter hospital based evaluation of 6388 patients in Turkish gynecologic oncology group centers. Turk Patoloji Derg 2013; 29:210-6.

28. Kulkarni SS, Kulkarni SS, Vastrad PP, Kulkarni BB, Markande AR, Kadakol GS, et al. Prevalence and distribution of high risk human papillomavirus (HPV) Types 16 and 18 in Carcinoma of cervix, saliva of patients with oral squamous cell carcinoma and in the general population in Karnataka, India. Asian Pac J Cancer Prev 2011; 12:645-8.

29. Sowjanya AP, Jain M, Poli UR, Padma S, Das M, Shah KV, BN et al. Prevalence and distribution of high risk human papillomavirus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India. BMC Infect Dis 2005; 5: 116.

30. De Oliveira CM, Fregnani JHTG, Carvalho JP, Longatto-Filho A, Levi JE. Human papilloma virus genotypes distribution in 175 invasive cervical cancer cases from Brazil. BMC Cancer 2013, 13:357.

31. Vu LT, Bui D, Le HT. Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign. BMC Cancer 2013, 13:53

32. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012; 30: 24-33.

33. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-65.

34. Ressler S, Scheider R, Dreier K, Laich A, Müller-Holzner E, Pircher H, et al. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma. Clin Cancer Res 2007; 13:7067-72.

35. Pirog EC, Kleter B, Olgae S, Bobkiewicz P, Lindeman J, Quint WG, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 2000; 157:1055-62.

36. Chen S, O’Sullivan H, Tabrizi SN, Fairley CK, Quinn MA, Garland SM. Prevalence and genotyping of HPV in cervical cancer among Australian women. Int J Gynaecol Obstet 1999; 67:163-8.

37. Krishnappa P, Mohamad IB, Lin YJ, Barua A. Expression of P16 in high-risk human papillomavirus related lesions of the uterine cervix in a government hospital, Malaysia. Diagn Pathol. 2014; 9:202.

38. SakikonoNishio, Takuma Fujii, Hiroshi Nishio, Kaori Kameyama, Miyuki Saito, Takashi Iwata, et al. p16 (ink4a) immunohistochemistry is a promising biomarker to predict the outcome of low grade cervical intraepithelial neoplasia: comparison study with HPV genotyping. J GynecolOnco 2013; 24: 215-221.

39. Balan R, Simion N, Giusca SE, Gheuca-Solovastru L, Gheorghita V, et al. Immunohistochemical assessment of p16, COX-2 and EGFR in HPV-positive cervical squamous intraepithelial lesions. Rom J Morphol Embryol. 2011; 52:1187-94.

40. Wu H, Shi H, Kong L. Relationship of HPVL1 and p16 expression with different cervical lesions. Sci Res Essays 2011; 6: 3724-8.

41. Yu L, Wang L, Zhong J, Chen S. Diagnostic value of p16INK4A, Ki-67, and human papillomavirus L1 capsid protein immunochemical staining on cell blocks from residual liquid-based gynecologic cytology specimens. Cancer Cytopathol 2010; 118:47-55.

42. Volgareva G, Zavalishina L, Andreeva Y, Frank G, Krutikova E, Golovina D, et al. Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells. BMC Cancer 2004, 4:58

43. Branca M, Ciotti M, Santini D, Di Bonito L, Giorgi C, Benedetto A, et al. P16 (INK4A) expression is related to grade of CIN and high risk human papillomavirus but
does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 2004; 23:354-65.

44. Bahnassy AA, Zakri AR, Saleh M, Lotuyef M, Moneir M, Shawki O. The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma. BMC Clin Pathol 2007; 7:4.

45. Ishikawa M, Fujii T, Saito M, Nindl I, Ono A, Kubushiro K, et al. Overexpression of p16 INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia. Int J Gynecol Cancer 2006; 16:347-53.

46. Lili C, Guoqing Y, Haiwei W, Yan C. Expression of HPV16/18, P16, CK17, Ki67 in cervical squamous epithelial lesions. Cancer Res Clin 2015; 27:113-116.

47. Wu J, Li X, Zhu W, Liu X. Detection and pathological value of papillomavirus DNA and p16INK4A and p53 protein expression in cervical intraepithelial neoplasia. Oncol Lett 2014; 7:738-744.

48. Guo M, Baruch AC, Silva EG, Jan YJ, Lin E, Sneige N, et al. Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neoplasia and cervical carcinoma. Am J Clin Pathol 2011; 135:212-20.

49. Benevolo M, Mottolese M, Marandino F, Vocaturo G, Sindico R, Piperno G, et al. Immunohistochemical expression of p16 (INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol 2006; 19:384-91.

50. Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002; 26:1389-99.

51. Klaes R, Friedrich T, Spitzkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16 (INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92:276-84.

52. Ikeda K, Tate G, Suzuki T, Mitsuya T. Coordinate expression of cytokeratin 8 and cytokeratin 17 immunohistochemical staining in cervical intraepithelial neoplasia and cervical squamous cell carcinoma: an immunohistochemical analysis and review of the literature. Gynecol Oncol 2008; 108:598-602.

53. Carrilho C, Alberto M, Buane L, David L. Keratins 8, 10, 13, and 17 are useful markers in the diagnosis of human cervix carcinomas. Hum Pathol. 2004; 35:546-51.

54. Martens JE, Arends J, Van der Linden PJ, De Boer BA, Helmerhorst TJ. Cytokeratin 17 and p63 are markers of the HPV target cell, the cervical stem cell Anticancer Res. 2004; 24:771-5.

55. Maddox P, Sasieni P, Szarewski A, Anderson M, Hanby A. Differential expression of keratins 10, 17, and 19 in normal cervical epithelium, cervical intraepithelial neoplasia, and cervical carcinoma. J Clin Pathol 1999; 52:41-6.

56. Carrilho C, Cirnes L, Alberto M, Buane L, Mendes N, David L. Distribution of HPV infection and tumor markers in cervical intraepithelial neoplasia from cone biopsies of Mozambican women. J Clin Pathol 2005; 58:61-8.

How to cite this article:
Chaloob M, G. Hussein A, Qasim B. Correlation of P16 (INK4a) and CK17 to HPV (16E6+18E6) in Premalignant and Malignant Lesions of Uterine Cervix: A Clinicopathologic Study. Iran J Pathol. 2016; 11(4): 377 - 390